生物制药公司Oragenics Inc. (NYSE American: OGEN) 已宣布与Duck Flats Pharma达成战略合作,旨在共同支持其脑震荡治疗项目的新药临床申请准备工作以及后续临床试验方案的设计。这一合作将整合双方在神经科学领域的专业知识和资源,加速该治疗方案的开发进程,以满足美国食品药品监督管理局的监管要求。
生物制药公司Oragenics Inc. (NYSE American: OGEN) 已宣布与Duck Flats Pharma达成战略合作,旨在共同支持其脑震荡治疗项目的新药临床申请准备工作以及后续临床试验方案的设计。这一合作将整合双方在神经科学领域的专业知识和资源,加速该治疗方案的开发进程,以满足美国食品药品监督管理局的监管要求。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.